Chronic Malignancies Working Party

CML & MDS & Ph-neg MPN

Activities of the working party and subcommittees

Chair: Ibrahim Yakoub-Agha
Secretary: Patrick Hayden
E-mail address: cmwpebmt@lumc.nl

Selected Upcoming Analyses CML 2020

Prognostic value of additional cytogenetic abnormalities in CML patients at transplantation. Caers J et al.

Outcome of CML post haplo-identical cell transplantation as compared to MRD and MUD. Onida F et al.

Comparison of haplo-identical (HID) transplant to matched sibling donor (MRD) and MUD in patients with CML blast crisis (de novo or secondary). Sheth V

Post-Transplant Scoring System for CML Based on Retrospective Analysis of Patients Surviving more than 100 Days after Allogeneic HSCT. Mappoura M et al.

Call for patient identification

Myelodysplastic Syndromes (MDS) and Paroxysmal Nocturnal Hemoglobinuria (PNH)

On behalf of the Severe Aplastic Anemia Working Party (SAAWP) and the Chronic Malignancies Working Party (CMWP), we are looking for centers that have treated patients with one of the two below clinical associations of PNH with MDS:

1. MDS with PNH clones – with small PNH clones and no evidence of haemolysis (the subclinical PNH)
2. MDS-PNH syndromes – with clinical and laboratory evidence of haemolysis (the clinical PNH)

If you have treated such a patient, please send the Unique Identification Code (UIC) to cmwpebmt@lumc.nl.

Active data request

Outcomes of patients who received an allogeneic hematopoietic stem cell transplantation (HSCT) for MDS or sAML after a prior diagnosis of a plasma cell disorder (PCD)

Inclusion criteria:
- Diagnosis of PCD prior to the first allogeneic HSCT.
- MDS or sAML as main indication diagnosis for first allogeneic HSCT.
- Adults (≥18 years) at time of first allogeneic HSCT.

First allogeneic HSCT between 2006 and 2018. If you have potential eligible patients and did not receive the data request, please contact us at cmwpebmt@lumc.nl.

Poster Session

ePoster Area Myelodysplastic syndromes

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Therapy-Related Myelodysplastic Neoplasia: A Study from the Chronic Malignancies Working Party of the EBMT

Poster Session

ePoster Area Chronic leukemia and other myeloproliferative disorders

Determinants of Survival in Myelodysplasia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation: A Study by the Chronic Malignancies Working Party of EBMT

Recently published articles

Family Mismatched Allogeneic Stem Cell Transplantation for Myelodysplasia: Report from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation


The role of spleen size and splenectomy in determining outcome in allogeneic stem cell transplantation for myelofibrosis. Battipaglia G et al.

Post-Transplant Cyclophosphamide as GVHD Prophylaxis for Allogeneic Hematopoietic Stem Cell Transplantation for myelofibrosis as compared to standard GVHD prophylaxis: A CMWP Study

Chalandon Y et al.

State-of-the-art review: allogeneic stem cell transplantation for myelodysplasia in 2019


Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party


Mycophenolate and reduced-intensity Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes: A Retrospective Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation


Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplasia Patients Undergoing Allogeneic Transplantation: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation


Outcome of allogeneic hematopoietic stem cell transplantation in myelodysplasia: an unclassified retrospective study by the Chronic Malignancies Working Party of the EBMT


Determinants of Survival in Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Cell Transplantation


www.ebmt.org #EBMT20Virtual